Brianne Jahn
Corporate Officer/Principal bij LIANBIO
Vermogen: 69 397 $ op 30-04-2024
Actieve functies van Brianne Jahn
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
LIANBIO | Corporate Officer/Principal | 01-09-2021 | - |
Operationeel Directeur | 01-02-2020 | 01-09-2021 | |
Financieel Directeur/CFO | 01-02-2020 | 01-05-2021 | |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Directeur/Bestuurslid | - | - |
Loopbaan van Brianne Jahn
Eerdere bekende functies van Brianne Jahn
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01-04-2012 | 01-01-2020 |
Opleiding van Brianne Jahn
New York University | Masters Business Admin |
University of Massachusetts | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
China | 2 |
Operationeel
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
LIANBIO | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Health Technology |
- Beurs
- Insiders
- Brianne Jahn
- Ervaring